ImmuPharma plc (LON:IMM – Get Free Report) fell 15.1% during trading on Friday . The company traded as low as GBX 3.28 and last traded at GBX 3.38. 2,337,142 shares were traded during mid-day trading, a decline of 5% from the average daily volume of 2,465,374 shares. The stock had previously closed at GBX 3.98.
ImmuPharma Stock Down 15.1%
The firm has a market capitalization of £21.09 million, a price-to-earnings ratio of -9.14 and a beta of 3.01. The firm’s 50 day moving average is GBX 3.87 and its 200 day moving average is GBX 4.44.
ImmuPharma (LON:IMM – Get Free Report) last posted its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.84) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 633.14% and a net margin of 3,519.56%. On average, sell-side analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
